Why the study?
Do EACA and Trasylol prevent thromboplastin-induced intravascular coagulation in dogs?
Do EACA and Trasylol prevent thromboplastin-induced intravascular coagulation in dogs?
In a canine model, EACA and Trasylol effectively blocked the fibrinolytic process secondary to thromboplastin-induced intravascular coagulation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for antifibrinolytics in coagulation disorders; clinical translation from this canine model remains untested.
The elimination of iodine‐labelled fibrinogen was followed in 3 groups of dogs after: 1. thromboplastin infusion, 2. simultaneous infusions of thromboplastin and epsilon aminocaproic acid (EACA), and 3. simultaneous infusions of thromboplastin and Trasylol. Platelet count, fibrinogen concentration, radioactivity in plasma and in fibrinogen as well as hematocrit were determined. Thromboplastin caused changes of the same type as those previously obtained with thrombin, indicating the development of a fibrinolytic process, secondary to intravascular coagulation. The secondary changes were effectively blocked by pretreatment with EACA and Trasylol. The incidence of and mortality in thromboembolism suggest some anticoagulant effect of Trasylol. The antifibrinolytic activity of Trasylol is much stronger than the anticoagulant one. EACA too, seems to give some protection against thromboplastin‐induced coagulation.
No takes yet. Share an insight, caveat, or question.
Nordström et al. (1969) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: